As of my last update in October 2023, there is no widely recognized chemical substance known as "LX-1" with the CAS number "2647877-84-5." It is possible that this compound is a novel or proprietary substance that has not yet been extensively documented in public databases or scientific literature. Typically, chemical substances are characterized by their molecular structure, physical properties (such as melting point, boiling point, and solubility), chemical reactivity, and potential applications. To obtain specific information about LX-1, including its characteristics and uses, it would be advisable to consult specialized chemical databases, scientific publications, or proprietary sources that may have more detailed information on this compound. If LX-1 is related to a specific field, such as pharmaceuticals or materials science, additional context may help in identifying its properties and significance.

LX-1

2647877-84-5: As of my last update in October 2023, there is no widely recognized chemical substance known as "LX-1" with the CAS number "2647877-84-5." It is possible that this compound is a novel or proprietary substance that has not yet been extensively documented in public databases or scientific literature. Typically, chemical substances are characterized by their molecular structure, physical properties (such as melting point, boiling point, and solubility), chemical reactivity, and potential applications. To obtain specific information about LX-1, including its characteristics and uses, it would be advisable to consult specialized chemical databases, scientific publications, or proprietary sources that may have more detailed information on this compound. If LX-1 is related to a specific field, such as pharmaceuticals or materials science, additional context may help in identifying its properties and significance.

LX1, an anti-prostate cancer compound, specifically targets the androgen receptor (AR), AR variants, and the steroidogenic enzyme AKR1C3. It inhibits AKR1C3's enzymatic function, decreases the conversion of androstenedione to testosterone, and reduces the expression of both AR and AR-V7, subsequently downregulating their target genes. Additionally, LX1 is effective in overcoming tumor cell resistance to Enzalutamide, and when combined with Enzalutamide, it further suppresses tumor growth.

CAS 2647877-84-5

LX-1

LX1

Ref: TM-T200147